BOD

Pasha Sarraf, M.D., Ph.D.

Dr. Sarraf is a physician-scientist with extensive experience in the business of science and biotechnology. After years of training, he spent a decade serving a diverse base of clients at McKinsey & Company as a Partner and Co-leader in the life sciences practices focused on strategy, diligence and forecasting. He later joined Leerink Partners as a Managing Director and Senior Analyst providing commentary on companies focused on internal medicine and those with interests in autoimmune disorders and metabolism. Following Leerink Partners, Pasha joined Flagship Pioneering as an Operating Partner, where he led a team of scientists who discovered novel genetic circuits in Parkinson’s Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK. Subsequently, Pasha joined Matterhorn Biosciences as CEO and executive board member, where he built a supportive team and scaled the scientific effort to demonstrate the value of their TCR-based platform. In addition to Cue Biopharma, Dr. Sarraf is also a board member of PolarityBio and Praesidia Biotherapeutics, where he serves as Chairman. Dr. Sarraf obtained his M.D., Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachusetts General Hospital (MGH) and National Institutes of Health (NIH), focusing on vasculitis, scleroderma and genetic inflammatory disorders. Dr. Sarraf has authored over 50 publications and multiple patents for novel therapies and molecular targets.